---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-054933"
form_type: "8-K"
ticker: "CVRX"
cik: "0001235912"
company_name: "CVRx, Inc."
filed_at: "2024-04-30T23:59:59+00:00"
generated_at: "2026-06-03T04:07:09.950140+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# CVRx Q1 revenue $10.8M (+35% YoY); net loss $22.2M; FY guidance $50-53M

## Summary
- Q1 revenue $10.8M (+35% YoY); US HF revenue $9.7M (+43%); active implanting centers 190 (+56% YoY).
- Net loss $22.2M ($1.04/shr) vs $11.4M ($0.55) prior year; SG&A $28.3M (+84%) from stock-based comp modification for former CEO.
- Full-year 2024 revenue guidance $50-53M; Q2 2024 revenue expected $11.3-12.3M.
- Kevin Hykes appointed CEO Feb 12; BeAT-HF data published in European Journal of Heart Failure.
- Compensation Committee approved $50k bonus to Paul Verrastro for management transition support.

## SEC filing metadata
- accession: 0001104659-24-054933
- form_type: 8-K
- ticker: CVRX
- cik: 0001235912
- company_name: CVRx, Inc.
- filed_at: 2024-04-30T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1235912/000110465924054933/0001104659-24-054933-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1235912/000110465924054933/tm2412998d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-054933
- JSON: https://secwatch.observer/filing/0001104659-24-054933.json
- Plain text: https://secwatch.observer/filing/0001104659-24-054933.txt

## Key facts
- Earnings Releases
  CVRx, Inc. reported the first quarter of 2024 results: revenue $10.8 million, net income $22.2 million, or $1.04 per share, EPS $1.04 per share. Guidance reaffirmed.
  - Period: the first quarter of 2024
  - Revenue: $10.8 million
  - Net income: $22.2 million, or $1.04 per share
  - EPS: $1.04 per share
  - Guidance: reaffirmed
  - Result: reported results
  source text: cardiovascular diseases, today announced its financial and operating results for the first quarter of 2024. Recent Highlights · Total revenue for the first quarter 2024 was $ 10.8 million, an increase of 35 % over the prior year quarter · U.S. Heart Failure (HF) revenue for the first quarter of 2024 was $ 9.7 million, an increase of 43 % over the prior year
  evidence_url: https://www.sec.gov/Archives/edgar/data/1235912/000110465924054933/0001104659-24-054933-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.